Literature DB >> 8895324

Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production.

G Renier1, I Clément, A C Desfaits, A Lambert.   

Abstract

GH has been demonstrated to play a physiological role in the priming of macrophages for tumor necrosis factor-alpha (TNF alpha) synthesis. Although evidence has been presented that GH exerts this effect by an indirect mechanism, the mediators of GH stimulation of TNF alpha synthesis have not been identified. Because insulin-like growth factor-I (IGF-I) is a major mediator of many GH effects, in the present study we investigated the direct in vitro effect of this growth factor on macrophage TNF alpha production. Treatment of murine macrophages with physiological concentrations of IGF-I (0.13-130 nM) enhanced both basal and lipopolysaccharide-stimulated macrophage TNF alpha release and messenger RNA levels. Induction of basal TNF alpha production was also observed after treatment of the cells with supraphysiological concentrations of insulin (130-1300 nM). Exposure of human monocytes to IGF-I led to a similar increase of basal TNF alpha production and messenger RNA expression. Preexposure of macrophages with specific antibodies against IGF-I and IGF-I receptor before IGF-I addition resulted in a complete abrogation of the stimulatory effect of IGF-I on TNF alpha production, indicating that specific binding of IGF-I to its receptor is required for macrophage TNF alpha induction by IGF-I. In contrast to the stimulatory effect of IGF-I, neither GH (0.1-10 micrograms/ml) nor IGF-II (0.13-130 nM) enhanced macrophage TNF alpha release in vitro. To assess the role of the tyrosine kinase system in mediating IGF-I-induced basal TNF alpha production, macrophages were preincubated with the specific tyrosine kinase inhibitors, genistein and tyrphostin A9, before IGF-I exposure. Addition of these compounds resulted in a dose-dependent inhibition of the stimulatory effect of IGF-I on macrophage TNF alpha release, indicating that protein tyrosine kinase activation is required for TNF alpha stimulation by IGF-I. Taken together, these results demonstrate that IGF-I is a monocyte/macrophage activating factor that enhances TNF alpha production, and that such effect is mediated via the IGF-I receptor and involves tyrosine kinase activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895324     DOI: 10.1210/endo.137.11.8895324

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  35 in total

1.  Overload training inhibits phagocytosis and ROS generation of peritoneal macrophages: role of IGF-1 and MGF.

Authors:  Weihua Xiao; Peijie Chen; Ru Wang; Jingmei Dong
Journal:  Eur J Appl Physiol       Date:  2012-05-17       Impact factor: 3.078

2.  Myeloid Cell-Restricted Insulin/IGF-1 Receptor Deficiency Protects against Skin Inflammation.

Authors:  Jana Knuever; Sebastian Willenborg; Xiaolei Ding; Mehmet D Akyüz; Linda Partridge; Carien M Niessen; Jens C Brüning; Sabine A Eming
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

Review 3.  IGF-1 and cardiovascular disease.

Authors:  Yusuke Higashi; Sandeep Gautam; Patrick Delafontaine; Sergiy Sukhanov
Journal:  Growth Horm IGF Res       Date:  2019-01-31       Impact factor: 2.372

4.  Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Shaw-Yung Shai; Svitlana Danchuk; Richard Tang; Patricia Snarski; Zhaohui Li; Patricia Lobelle-Rich; Meifang Wang; Derek Wang; Hong Yu; Ronald Korthuis; Patrice Delafontaine
Journal:  Circulation       Date:  2016-05-06       Impact factor: 29.690

Review 5.  Exploring immunomodulation by endocrine changes in Lady Windermere syndrome.

Authors:  M R Holt; J J Miles; W J Inder; R M Thomson
Journal:  Clin Exp Immunol       Date:  2019-02-27       Impact factor: 4.330

6.  Hepatic JAK2 protects against atherosclerosis through circulating IGF-1.

Authors:  Tharini Sivasubramaniyam; Stephanie A Schroer; Angela Li; Cynthia T Luk; Sally Yu Shi; Rickvinder Besla; David W Dodington; Adam H Metherel; Alex P Kitson; Jara J Brunt; Joshua Lopes; Kay-Uwe Wagner; Richard P Bazinet; Michelle P Bendeck; Clinton S Robbins; Minna Woo
Journal:  JCI Insight       Date:  2017-07-20

7.  MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus.

Authors:  Zall Hirschstein; Gautam Reddy Vanga; Guirong Wang; Zachary M Novakovic; Patricia Grasso
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-07-29       Impact factor: 3.770

Review 8.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

Review 9.  IGF-1, oxidative stress and atheroprotection.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Asif Anwar; Shaw-Yung Shai; Patrice Delafontaine
Journal:  Trends Endocrinol Metab       Date:  2010-01-12       Impact factor: 12.015

10.  Presence of irregularity in region between -1115 and -784 nt in P1 promoter of insulin-like growth factor-1 gene may indicate beneficial effect on coronary arteries in a group of patients with stable angina: preliminary data.

Authors:  Pawel Burchardt; Witold Nowak; Anna Gozdzicka-Jozefiak; Rafal Link; Tomasz Grotowski; Anna Wisniecka; Tomasz Siminiak
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.